Charles Schwab Investment Management Inc Macrogenics Inc Transaction History

Charles Schwab Investment Management Inc

  • $515 Billion
  • Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 492,765 shares of MGNX stock, worth $1.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
492,765
Previous 510,505 3.47%
Holding current value
$1.6 Million
Previous $2.17 Million 25.27%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$3.0 - $5.55 $53,220 - $98,457
-17,740 Reduced 3.47%
492,765 $1.62 Million
Q2 2024

Aug 12, 2024
SELL
$3.31 - $18.51 $41,179 - $230,282
-12,441 Reduced 2.38%
510,505 $2.17 Million
Q1 2024

May 08, 2024
SELL
$9.77 - $21.47 $3.03 Million - $6.67 Million
-310,554 Reduced 37.26%
522,946 $7.7 Million
Q4 2023

Feb 06, 2024
BUY
$4.48 - $10.11 $36,337 - $82,002
8,111 Added 0.98%
833,500 $8.02 Million
Q3 2023

Nov 08, 2023
BUY
$4.48 - $6.19 $465,239 - $642,819
103,848 Added 14.39%
825,389 $3.85 Million
Q2 2023

Aug 09, 2023
BUY
$4.62 - $7.54 $461,990 - $753,984
99,998 Added 16.09%
721,541 $3.86 Million
Q1 2023

May 11, 2023
BUY
$4.82 - $7.24 $1.02 Million - $1.54 Million
212,180 Added 51.83%
621,543 $4.46 Million
Q4 2022

Feb 13, 2023
BUY
$3.34 - $6.98 $25,811 - $53,941
7,728 Added 1.92%
409,363 $2.75 Million
Q3 2022

Nov 14, 2022
BUY
$3.01 - $5.22 $83,232 - $144,343
27,652 Added 7.39%
401,635 $1.39 Million
Q2 2022

Aug 15, 2022
SELL
$2.25 - $9.99 $218,220 - $968,900
-96,987 Reduced 20.59%
373,983 $1.1 Million
Q1 2022

May 13, 2022
BUY
$8.12 - $16.9 $119,981 - $249,714
14,776 Added 3.24%
470,970 $4.15 Million
Q4 2021

Feb 11, 2022
BUY
$15.91 - $21.88 $98,069 - $134,868
6,164 Added 1.37%
456,194 $7.32 Million
Q3 2021

Nov 16, 2021
SELL
$19.74 - $28.7 $8,961 - $13,029
-454 Reduced 0.1%
450,030 $9.42 Million
Q2 2021

Aug 16, 2021
BUY
$20.49 - $35.63 $912,747 - $1.59 Million
44,546 Added 10.97%
450,484 $12.1 Million
Q1 2021

May 17, 2021
BUY
$18.99 - $33.2 $222,904 - $389,701
11,738 Added 2.98%
405,938 $12.9 Million
Q4 2020

Feb 16, 2021
BUY
$19.41 - $26.0 $856,466 - $1.15 Million
44,125 Added 12.6%
394,200 $9.01 Million
Q3 2020

Nov 13, 2020
BUY
$24.69 - $31.6 $671,814 - $859,836
27,210 Added 8.43%
350,075 $8.82 Million
Q2 2020

Aug 14, 2020
BUY
$5.2 - $29.12 $89,861 - $503,222
17,281 Added 5.66%
322,865 $9.02 Million
Q1 2020

May 15, 2020
BUY
$4.28 - $12.11 $25,337 - $71,691
5,920 Added 1.98%
305,584 $1.78 Million
Q4 2019

Feb 07, 2020
BUY
$7.95 - $12.27 $44,718 - $69,018
5,625 Added 1.91%
299,664 $3.26 Million
Q3 2019

Nov 08, 2019
BUY
$12.44 - $17.48 $387,132 - $543,977
31,120 Added 11.84%
294,039 $3.75 Million
Q2 2019

Aug 09, 2019
BUY
$14.51 - $19.71 $345,033 - $468,684
23,779 Added 9.94%
262,919 $4.46 Million
Q1 2019

May 14, 2019
SELL
$11.11 - $25.6 $61,460 - $141,619
-5,532 Reduced 2.26%
239,140 $4.3 Million
Q4 2018

Feb 14, 2019
SELL
$11.75 - $21.42 $26,002 - $47,402
-2,213 Reduced 0.9%
244,672 $3.11 Million
Q3 2018

Nov 13, 2018
BUY
$19.26 - $23.46 $401,474 - $489,023
20,845 Added 9.22%
246,885 $5.29 Million
Q2 2018

Aug 08, 2018
BUY
$19.78 - $24.67 $1.02 Million - $1.27 Million
51,577 Added 29.56%
226,040 $4.67 Million
Q1 2018

May 07, 2018
SELL
$18.89 - $32.46 $12,146 - $20,871
-643 Reduced 0.37%
174,463 $4.39 Million
Q4 2017

Jan 17, 2018
BUY
$16.19 - $20.3 $99,050 - $124,195
6,118 Added 3.62%
175,106 $3.33 Million
Q3 2017

Nov 13, 2017
BUY
$15.52 - $18.94 $2.62 Million - $3.2 Million
168,988
168,988 $3.12 Million

Others Institutions Holding MGNX

# of Institutions
134
Shares Held
55.5M
Call Options Held
215K
Put Options Held
238K
View Full List

About MACROGENICS INC

MGNX Quotes by TradingView
  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $199M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email